Anbio Biotechnology Class A Ordinary Shares
NNNN · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $11,761 | $10,310 | $9,688 | $10,561 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1,065 | $4,615 | $1,885 | $4 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5,709 | $3,841 | $4,177 | $4,582 |
| Total Curr. Assets | $18,534 | $18,766 | $15,750 | $15,147 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $387 | $177 | $62 | $277 |
| Total NC Assets | $387 | $177 | $62 | $280 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $18,922 | $18,943 | $15,812 | $15,427 |
| Liabilities | – | – | – | – |
| Payables | $1,625 | $479 | $827 | $1,308 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $105 | $49 | $166 | $34 |
| Total Curr. Liab. | $1,730 | $528 | $993 | $1,342 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,730 | $528 | $993 | $1,342 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $14 | $14 | $14 | $14 |
| Retained Earnings | $17,174 | $18,397 | $14,801 | $14,068 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $4 | $4 | $4 | $4 |
| Total Equity | $17,192 | $18,415 | $14,819 | $14,086 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $18,922 | $18,943 | $15,812 | $15,427 |
| Net Debt | -$11,761 | -$10,310 | -$9,688 | -$10,561 |